Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 2,908 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Aging, Skeletal Muscle
Interventions: Non-Exercise Control, Resistance Exercise Training, Placebo, HMB+VitD; Behavioral · Dietary Supplement
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Carotid Stenosis
Interventions: Minocycline, Placebo oral capsule; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: 22q11 Deletion Syndrome
Interventions: NB-001, Placebo; Drug · Other
Lead sponsor: Nobias Therapeutics, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Aurora, Colorado • Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Healthy
Interventions: Wax Ester Marine Oil, Ethyl Ester Marine Oil; Other
Lead sponsor: Calanus; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Fabry Disease, Neuropathic Pain
Interventions: Gabapentin, placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Major Depressive Disorder, Insomnia
Interventions: SAGE-217, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 28
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Garden Grove, California + 24 more

Conditions: Lung Cancer
Interventions: Minocycline, Placebo, Questionnaires; Drug · Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Cancer, Fatigue
Interventions: Methylphenidate, Nursing Telephone Intervention, Placebo, Non NTI; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Obesity
Interventions: Canagliflozin (JNJ-28431754), Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 35
States / cities: Hot Springs, Arkansas • Walnut Creek, California • Westlake Village, California + 32 more

Conditions: Systemic Lupus Erythematosus
Interventions: GLPG3667, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Tucson, Arizona • La Jolla, California • Rancho Mirage, California + 16 more

Conditions: Acute Myeloid Leukemia
Interventions: Pracinostat, Placebos, Azacitidine; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 30
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 25 more

Conditions: Refractive Error
Interventions: Omega-3 Fatty Acid Supplements; Dietary Supplement
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 28 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Microvascular Coronary Artery Disease
Interventions: SAR407899, Placebo, Adenosine, Regadenoson, 13N-ammonia, 82Rubidium; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Jacksonville, Florida • Wellington, Florida + 3 more

Conditions: Healthy Volunteer
Interventions: AZD7325, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 50 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Carfilzomib, Dexamethasone, Lenalidomide (Control); Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Detroit, Michigan

Conditions: Psoriasis
Interventions: Cap SRT2104, Tab SRT2104 slow release, Tab SRT2104 intermediate release, Tab SRT2104 fast release, Selected formulations of SRT2104 from Part 1, Selected formulations of SRT2104 from Part 1 single alternative dose; Drug
Lead sponsor: Sirtris, a GSK Company; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Autism Spectrum Disorder
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 34
States / cities: Anaheim, California • Imperial, California • Orange, California + 28 more

Conditions: HIV-1 Infection
Interventions: Islatravir, Placebo to Islatravir, Doravirine, Placebo to Doravirine, Lamivudine, Placebo to Lamivudine, Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Doravirine/Islatravir; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 7 more

Conditions: Recurrent Bacterial Vaginosis
Interventions: Metronidazole (male partner), Placeob (male partner); Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 50 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pell City, Alabama

Conditions: Dental Pain
Interventions: Oxycodone, Buprenorphine, Placebo Film, Placebo Capsule; Drug
Lead sponsor: BioDelivery Sciences International; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 3
States / cities: Austin, Texas • San Marcos, Texas • Salt Lake City, Utah

Conditions: Carcinoid Syndrome
Interventions: Telotristat etiprate, Octreotide LAR Depot, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 9
States / cities: Little Rock, Arkansas • San Francisco, California • Indianapolis, Indiana + 6 more

Conditions: Autism
Interventions: docosahexaenoic acid (DHA), Placebo; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 3 Years to 10 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Moderate to Severe Ulcerative Colitis
Interventions: Double-Blind 0.2mg CBP-307, Double-Blind Placebo, Open-label CBP-307, Double-Blind 0.1mg CBP-307; Drug
Lead sponsor: Connect Biopharm LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • Mission Hills, California • Hialeah, Florida + 9 more

Conditions: Urinary Tract Infection
Interventions: Once Daily Cranberry Capsule, Twice Daily Cranberry Capsules; Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: 60 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Independent and Combined Effects of Resistance Exercise Training and β-hydroxy β-methylbutyrate Plus Vitamin D

A Study of the Effects of Minocycline on Cognitive Function After Carotid Endarterectomy

NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

Study to Evaluate the Acute Bioavailability of EPA and DHA From a DietarySupplement in Healthy Men and Women

Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease

A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia

Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy

Methylphenidate and a Nursing Telephone Intervention for Fatigue

A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Epithelial Healing and Visual Outcomes Using Omega-3 Therapy Before and After Photorefractive Keratectomy (PRK) Surgery

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers

Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

Randomized Controlled Trial of Treatment of Male Partners of Women With BV

Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Docosahexaenoic Acid in the Treatment of Autism

A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

Cranberry for UTI Prevention in Residents of Long Term Care Facilities